Compare UBXG & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBXG | DXR |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 61.1M |
| IPO Year | 2024 | N/A |
| Metric | UBXG | DXR |
|---|---|---|
| Price | $1.96 | $14.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 16.2K | 3.0K |
| Earning Date | 12-22-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $29,674,534.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $40.03 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $6.55 |
| 52 Week High | $4.64 | $14.76 |
| Indicator | UBXG | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 63.96 |
| Support Level | $1.93 | $12.00 |
| Resistance Level | $2.08 | $12.90 |
| Average True Range (ATR) | 0.12 | 0.46 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 11.11 | 72.16 |
U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.